Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-Cirrhosis
NCT06419374Phase 3Recruiting
- Sponsor
- Roche
- Start
- May 2024
- Primary completion
- Jun 2028
- Modality
- Carrier/Scaffold Proteins
- Countries
- 25
01
Overview
A Phase 3 trial of pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH), Cirrhosis, sponsored by Roche. Started May 2024; status: recruiting.
02
Drugs
pegozafermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on NCT06419374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419374.